Robeco Institutional Asset Management B.V. Acquires 164,432 Shares of Zoetis Inc. $ZTS

Key Points

• Robeco Institutional Asset Management B.V. increased its stake in Zoetis Inc. by 43.2%, acquiring an additional 164,432 shares, bringing its total holdings to 545,448 shares worth approximately $85 million.
• Zoetis reported a quarterly EPS of $1.76, surpassing analyst expectations of $1.62, with revenues reaching $2.46 billion, representing a 4.2% increase from the previous year.
• Approximately 92.80% of Zoetis's stock is owned by institutional investors, with several hedge funds, including the Vanguard Group, also increasing their stakes in the company over recent quarters.

Robeco Institutional Asset Management B.V. increased its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 43.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 545,448 shares of the company's stock after buying an additional 164,432 shares during the period. Robeco Institutional Asset Management B.V. owned 0.12% of Zoetis worth $85,063,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Vanguard Group Inc. raised its stake in shares of Zoetis by 0.5% during the first quarter. Vanguard Group Inc. now owns 41,556,164 shares of the company's stock worth $6,842,222,000 after buying an additional 189,287 shares during the last quarter. Polen Capital Management LLC raised its stake in shares of Zoetis by 17.6% during the first quarter. Polen Capital Management LLC now owns 8,796,847 shares of the company's stock worth $1,448,401,000 after buying an additional 1,313,653 shares during the last quarter. Northern Trust Corp raised its stake in shares of Zoetis by 1.2% during the first quarter. Northern Trust Corp now owns 6,504,902 shares of the company's stock worth $1,071,032,000 after buying an additional 78,508 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Zoetis by 2.2% during the first quarter. Goldman Sachs Group Inc. now owns 5,146,024 shares of the company's stock worth $847,293,000 after buying an additional 109,791 shares during the last quarter. Finally, Brown Advisory Inc. raised its stake in shares of Zoetis by 7.6% during the first quarter. Brown Advisory Inc. now owns 4,408,542 shares of the company's stock worth $725,866,000 after buying an additional 312,746 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Stock Down 0.3%

Shares of ZTS stock opened at $146.46 on Friday. The firm has a fifty day moving average of $149.89 and a 200-day moving average of $155.26. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05. Zoetis Inc. has a 12-month low of $139.34 and a 12-month high of $196.55. The company has a market capitalization of $64.91 billion, a price-to-earnings ratio of 25.21, a P/E/G ratio of 2.36 and a beta of 0.90.

Zoetis (NYSE:ZTS - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.14. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. During the same quarter in the prior year, the firm earned $1.56 earnings per share. The firm's revenue was up 4.2% compared to the same quarter last year. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and lowered their target price for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Piper Sandler upped their target price on shares of Zoetis from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Monday, August 11th. Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research note on Thursday, July 17th. Argus reaffirmed a "buy" rating and issued a $190.00 target price on shares of Zoetis in a research note on Tuesday, September 9th. Finally, Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Five research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.